Os therapies announces overall and event free survival key subgroup data for ost-her2 in recurrent, fully resected, pulmonary metastatic osteosarcoma

New york, new york--(newsfile corp. - october 22, 2025) - os therapies inc. (nyse american: ostx) ("os therapies" or "the company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced additional overall and event free survival data generated from the company's 41-patient phase 2b clinical trial of its off-the-shelf immunotherapeutic candidate ost-her2 in recurrent, fully resected, pulmonary metastatic osteosarcoma (the "phase 2b osteosarcoma trial"). the company previously announced statistically significant positive final 2-year overall survival data from its phase 2b osteosarcoma trial on october 10, 2025.
OST Ratings Summary
OST Quant Ranking